-Dow Jones, citing WSJ
Keros Therapeutics Presents Preclinical Data From Its KER-012 Program At The American Heart Association 2022 Scientific Sessions
Keros Therapeutics, Inc. (“Keros”) (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from